Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes (CIP347)

NCT06739811 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-03-21
Last updated
2026-09-22

Condition(s) studied

Type I Diabetes

Investigational drug(s) / intervention(s)

Implantable Insulin Pump System

Implantable Insulin Pump System: Medtronic Implantable Insulin Pump System (MIIPS 2020)

Study summary

The purpose of this study is to evaluate the clinical performance of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in adult patients with Type 1 diabetes mellitus that cannot be controlled with subcutaneous insulin therapy (including external pump), and presenting with frequent, otherwise unexplained severe hyper- and/or hypoglycemia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Subject is aged ≥ 18 years old. 2. Subject has a clinical diagnosis of type 1 diabetes for ≥ 6 months prior to screening as determined via medical record or source documentation by an individual qualified to make a medical diagnosis. 3. Subject with type 1 diabetes mellitus that cannot be controlled with subcutaneous insulin therapy (including external pump), presenting with frequent, otherwise unexplained severe hyper-and/or hypoglycaemia. 4. Subject has access to a reliable support person, defined as an individual who has daily contact with the subject and knows who to contact in the event of an emergency (i.e., caregiver). 5. Subject has the physical and intellectual ability (in the opinion of the study investigator) to operate the MIIP system and to comply with the data reporting requirements of the study. 6. Subject is willing and able to sign and date informed consent, comply with all study procedures as required during the study. Exclusion Criteria: 1. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or device before enrollment into this study, that could impact the outcomes of this study; as per investigator and sponsor judgment. 2. Subject has any other disease or condition that may increase risks during the implant procedure or may preclude the subject from participating in the study, as determined by a physician who is not the principal investigator. 3. Subject has any known or suspected allergy to insulin or implantable materials of the MIIPS (pump and catheter) as determined by a physician. 4. Subject is a woman who is pregnant, or of childbearing potential, or lactating, and who is neither surgically sterile, nor using contraceptives (devices, oral, implanted or other physician-approved contraceptive), or willing to use them, at the time of enrollment. 5. Subject is vulnerable, legally incompetent or illiterate. 6. Residence or planned non-pressurized travel at elevations above 10000 feet/3048 meters (commercial airline travel is acceptable). 7. Planning to engage in activities requiring a descent greater than or equal to 10 feet/3 meters below sea level. 8. Subject has an active infection requiring antibiotic treatment. 9. Subject is a person whose body size is not sufficient to accept implantable pump bulk and weight. 10. Subject has a life expectancy of less than 9 months. 11. Subject has diagnosis of illicit drugs abuse disorder. 12. Subject has diagnosis of marijuana abuse disorder. 13. Subject has diagnosis of prescription drugs abuse disorder. 14. Subject has diagnosis of alcohol abuse disorder. 15. Subject who is unwilling or unable to monitor their glucose level or wear a personal continuous glucose monitor. 16. Subject who is unwilling or unable to make programming modifications to the pump based on glucose level readings.

Primary outcome measure(s)

  • Refill accuracy of MIIPS 2020 — 6 months
    Refill Accuracy= (Total Actual Volume Dispensed)/(Total Theoretical Volume Dispensed) after the last refill cycle

Trial sites (11)

FacilityCityRegionStatus
Hôpital Saint André -Centre Hospitalier Universitaire de Bordeaux Bordeaux France Not Yet Recruiting
Centre Hospitalier Sud Francilien Corbeil-Essonnes France Not Yet Recruiting
CHU Lille - Hôpital Huriez Lille France Active Not Recruiting
Centre Hospitalier Universitaire De Montpellier Montpellier France Active Not Recruiting
CHU de Nancy - Hôpital d'Adultes de Brabois Nancy France Not Yet Recruiting
CHU de Toulouse - Hôpital Rangueil Toulouse France Active Not Recruiting
CHU Dijon Bourgogne Dijon France Active Not Recruiting
Hôpital Européen Marseille Marseille France Active Not Recruiting
Hôpital Lariboisière & Fernand-Widal Paris France Active Not Recruiting
Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil Strasbourg France Active Not Recruiting
Isala Zwolle Zwolle Netherlands Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06739811 on ClinicalTrials.gov ↗ ← All trials in France